Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia
Clinical and Translational Science · 2026-05 · 19 (5)
DOI: 10.1111/cts.70545 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 09.05.2026. Verfasst von Hengbang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Healthquest Pharma Co. Ltd., Guangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Diet, High-Fat, Food-Drug Interactions, Protein Kinase Inhibitors. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangzhou Healthquest Pharma Co. Ltd.
Abstract (Originalsprache)
Olverembatinib is approved in China to treat patients with chronic‐ or accelerated‐phase chronic myeloid leukemia (CML‐CP or CML‐AP) with T315I mutations and CML‐CP that is resistant and/or intolerant to first‐ and second‐generation tyrosine kinase inhibitors. The objective of this study was to determine the effects of a high‐fat meal on the pharmacokinetics of olverembatinib in patients with CML. Twelve participants were enrolled and received olverembatinib treatment over two periods, with a washout of 7 days between consecutive doses. Pharmacokinetics and safety were assessed in all participants. When olverembatinib was administered with a high‐fat meal, the maximum plasma concentration ( C max ) and area under the plasma concentration versus time curve from time 0 to infinity (AUC 0–∞ ) of olverembatinib increased by 105.74% and 69.74%, respectively, compared to fasting conditions. The median time to maximum plasma concentration ( T max ) of olverembatinib was not affected when it was administered with a high‐fat meal, and the geometric mean terminal plasma half‐life ( t 1/2 ) was comparable between high‐fat meal and preprandial conditions (26.8 vs. 31.1 h). The safety profile of olverembatinib was consistent with observations from previous studies; all treatment‐related adverse events were mild, and no serious adverse event was reported. These results indicate that consumption of a high‐fat meal 30 min before administering olverembatinib can increase its plasma exposure to some extent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.
- Ascentage Pharma Group Inc., Rockville, Maryland, USA.
ORCID-Profile: Hengbang Wang, Yun Yang, Zi Chen, Min Yu, Lixin Jiang, Lichuang Men, Hua Yan, Dajun Yang, Yifan Zhai
Förderung
- Guangzhou Healthquest Pharma Co. Ltd
Zitieren
APA
Wang, H., Yang, Y., Chen, Z., Yu, M., Jiang, L., Men, L., Yan, H., Yang, D., & Zhai, Y. (2026). Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70545
Vancouver
Wang H, Yang Y, Chen Z, Yu M, Jiang L, Men L, et al. Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70545
BibTeX
@article{Wang2026,
author = {Wang, Hengbang and Yang, Yun and Chen, Zi and Yu, Min and Jiang, Lixin and Men, Lichuang and Yan, Hua and Yang, Dajun and Zhai, Yifan},
title = {Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {5},
doi = {10.1111/cts.70545}
}
EUVIMED